Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | PNMT | P11086 | 1/20 | 0.36 |
| ▸ | CD44 | P16070 | 1/20 | 0.36 |
| ▸ | OXTR | P30559 | 1/20 | 0.33 |
| ▸ | PRCP | P42785 | 1/20 | 0.32 |
| ▸ | RYR2 | Q92736 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | METAP2 | P50579 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL301628 | 0.78 | CA12 (0.44) | CA12CA9 | |
| SCHEMBL23194 | 0.78 | MAOA (0.46) | MAOBMAOAMETAP2MEN1CYP3A4 | |
| SCHEMBL1165406 | 0.76 | CA12 (0.52) | CA12CA9MAOBPNMTCD44 | |
| Hydrochloric Acid SCHEMBL32672905 | 0.74 | CA12 (0.50) | CA12CA9MAOBPNMTCD44 | |
| SCHEMBL130192 | 0.71 | — | — | |
| SCHEMBL8911202 | 0.69 | CA12 (0.38) | CA12CA9MAOBPNMTCD44 | |
| SCHEMBL5841463 | 0.69 | MAOA (0.48) | MAOBMAOAHTR2CMEN1CYP2D6 | |
| SCHEMBL13590042 | 0.68 | PNMT (0.65) | MAOBPNMTCD44OXTRRYR2 | |
| SCHEMBL10612 | 0.68 | — | — | |
| SCHEMBL29351494 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005037284-A1 | SORBITOL DEHYDROGENASE INHIBITOR AND HYPERTENSIVE AGENT COMBINATIONS | PFIZER PRODUCTS INC. (US) | 2005-04-28 | — | — | WO | claimed |
| EP-1337271-B1 | COMBINATION OF GABA AGONISTS AND SORBITOL DEHYDROGENASE INHIBITORS | PFIZER PROD INC (US) | 2004-11-03 | — | — | EP | claimed |
| US-20040077671-A1 | Sorbitol dehydrogenase inhibitors | CHU-MOYER MARGARET Y (US) | 2004-04-22 | — | — | US | claimed |
| US-20030186994-A1 | Combination of statins and sorbitol dehydrogenase inhibitors | MYLARI BANAVARA L (US) | 2003-10-02 | — | — | US | claimed |
| EP-1337271-A2 | COMBINATION OF GABA AGONISTS AND SORBITOL DEHYDROGENASE INHIBITORS | Pfizer Products Inc. (US) | 2003-08-27 | — | — | EP | claimed |
| US-6602875-B2 | Sorbitol dehydrogenase inhibitors | PFIZER INC | 2003-08-05 | — | — | US | claimed |
| EP-1326591-A2 | COMBINATION OF STATINS AND SORBITOL DEHYDROGENASE INHIBITORS | Pfizer Products Inc. (US) | 2003-07-16 | — | — | EP | claimed |
| US-6544998-B2 | For treatment of suffering from diabetic complications like diabetic neuropathy, nephropathy, cardiomyopathy, retinopathy, microangiopathy, macroangiopathy, cataracts and foot ulcers. | PFIZER INC | 2003-04-08 | — | — | US | claimed |
| US-20030065179-A1 | Sorbitol dehydrogenase inhibitors | CHU-MOYER MARGARET Y (US) | 2003-04-03 | — | — | US | claimed |
| US-20020091128-A1 | Combination of gaba agonists and sorbitol dehydrogenase inhibitors | MYLARI BANAVARA L (US) | 2002-07-11 | — | — | US | claimed |
| WO-2002043762-A2 | COMBINATION OF GABA AGONISTS AND SORBITOL DEHYDROGENASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2002-06-06 | — | — | WO | claimed |
| WO-2002032411-A2 | COMBINATION OF STATINS AND SORBITOL DEHYDROGENASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2002-04-25 | — | — | WO | claimed |
| EP-1185275-A1 | AMINOPYRIMIDINES AS SORBITOL DEHYDROGENASE INHIBITORS | Pfizer Products Inc. (US) | 2002-03-13 | — | — | EP | claimed |
| WO-2000059510-A1 | AMINOPYRIMIDINES AS SORBITOL DEHYDROGENASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-10-12 | — | — | WO | claimed |
| US-6936600-B2 | Sorbitol dehrydrogenase inhibitors | PFIZER INC (US) | 2005-08-30 | — | — | US | disclosed |
| WO-2005037284-A1 | SORBITOL DEHYDROGENASE INHIBITOR AND HYPERTENSIVE AGENT COMBINATIONS | PFIZER PRODUCTS INC. (US) | 2005-04-28 | — | — | WO | disclosed |
| US-6869943-B2 | Sorbitol dehydrogenase inhibitors | PFIZER INC (US) | 2005-03-22 | — | — | US | disclosed |
| EP-1185275-A1 | AMINOPYRIMIDINES AS SORBITOL DEHYDROGENASE INHIBITORS | Pfizer Products Inc. (US) | 2002-03-13 | — | — | EP | disclosed |
| US-20010056095-A1 | Salts of zopolrestat | MYLARI BANAVARA L (US) | 2001-12-27 | — | — | US | disclosed |
| WO-2000059510-A1 | AMINOPYRIMIDINES AS SORBITOL DEHYDROGENASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010056095-A1 | Salts of zopolrestat | SLC5A1, SLC5A2, SLC2A1 | CA12 2509/4885CA9 2414/4885MAOB 781/4885 |
| US-20030186994-A1 | Combination of statins and sorbitol dehydrogenase inhibitors | SORD, HMGCR, SCD | CA12 4543/4885CA9 2525/4885MAOB 1614/4885 |
| US-20040077671-A1 | Sorbitol dehydrogenase inhibitors | SLC5A1, SORD, SLC5A2 | CA12 4393/4885CA9 2402/4885MAOB 665/4885 |
| US-20030065179-A1 | Sorbitol dehydrogenase inhibitors | SLC5A1, SORD, SLC5A2 | CA12 4393/4885CA9 2402/4885MAOB 665/4885 |
| US-20020091128-A1 | Combination of gaba agonists and sorbitol dehydrogenase inhibitors | SORD, GABRE, SLC6A1 | CA12 4314/4885CA9 2719/4885MAOB 685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.